Released Dec 14, 2017, after the close
10-Q filed Dec 14, 2017, 75 days after period end · 0001193125-17-369457
Q3 2017 · 10-Q
Revenue$597.00K$597.00K no prior Q3 2016 on file+139.8% vs Q2 2017
Net Income-$9.84M-$9.84M N/M vs Q3 2016N/M vs Q2 2017
EPS Diluted-$36.02-$36.02 N/M vs Q3 2016N/M vs Q2 2017
Operating Income-$9,966,000N/M
Operating Cash Flowderived-$10,515,000—
Margins · derived
Operating margin-1669.3%
Net margin-1647.6%
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2017 | Q3 2016 |
|---|---|---|
| Revenue | $597.00K | — |
| Net Income | -$9.84M | -$6.32M |
| EPS Diluted | -$36.02 | -$23.23 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR